These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 3479632)

  • 1. Antitumor activity of a Streptococcus pyogenes preparation (OK-432). I. Sequential effector mechanisms following a single OK-432 injection in F344 rats leading to the rejection of syngeneic MADB106 tumor cells.
    Fukui H; Reynolds CW
    J Natl Cancer Inst; 1987 Nov; 79(5):1011-7. PubMed ID: 3479632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity of a Streptococcus pyogenes preparation (OK-432). II. Analysis of the cytotoxic lymphocytes induced by OK-432 injection into tumor-bearing F344 rats.
    Fukui H; Reynolds CW
    J Natl Cancer Inst; 1987 Nov; 79(5):1019-24. PubMed ID: 3500354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of cytotoxic polymorphonuclear leukocytes by in vivo administration of a streptococcal preparation, OK-432.
    Watabe S; Sendo F; Kimura S; Arai S
    J Natl Cancer Inst; 1984 Jun; 72(6):1365-70. PubMed ID: 6587156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Induction of LAK cells in peritoneal cavity of mice after ip injection of OK-432 and antitumor effect of these LAK cells].
    Ishida N; Saito M; Nanjo M
    Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2681-90. PubMed ID: 6508321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Production of a cytotoxic factor in mouse peritoneal fluid by OK-432, a streptococcal preparation].
    Yamamoto A; Nagamuta M; Usami H; Sugawara Y; Watanabe N; Niitsu Y; Urushizaki I
    Gan To Kagaku Ryoho; 1986 May; 13(5):1905-10. PubMed ID: 3707150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Anticancer effects of OK-432 (2). Anticancer actions of M phi activated by OK-432].
    Saito M; Aonuma E; Noda T; Nakadate I; Nanjo M; Ebina T; Ishida N
    Gan To Kagaku Ryoho; 1983 May; 10(5):1363-71. PubMed ID: 6870302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal antibody to a human salivary gland adenocarcinoma cell line: augmentation of antibody-dependent cell-mediated cytotoxicity activity by streptococcal preparation OK-432 in human salivary gland adenocarcinoma-bearing nude mice given the antibody.
    Kaji R; Yoshida H; Yanagawa T; Sato M
    J Biol Response Mod; 1989 Oct; 8(5):488-500. PubMed ID: 2552025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Successful adoptive immunotherapy with OK432-inducible activated natural killer cells on tumor-bearing mice].
    Yamaue H; Tanimura H; Iwahashi M; Tani M; Tsunoda T; Tabuse K
    Nihon Gan Chiryo Gakkai Shi; 1989 Dec; 24(11):2546-55. PubMed ID: 2614190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antitumor effect of OK-432 (3)--mechanisms of tumor growth inhibition by OK-432 induced activated macrophages].
    Nanjo M; Saito M; Aonuma E; Fujimura H; Nakamura T; Aso H; Yoshie O; Ebina T; Ishida N
    Gan To Kagaku Ryoho; 1985 Apr; 12(4):887-93. PubMed ID: 3885861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. OK-432-mediated augmentation of antitumor immunity and generation of cytotoxic T lymphocytes.
    Ujiie T
    Jpn J Exp Med; 1987 Apr; 57(2):103-15. PubMed ID: 3499533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Combined effect of intraperitoneally administered OK-432 and recombinant interleukin (rIL-2) against mouse tumors].
    Fujioka T; Shiraishi M; Tanji S; Koike H; Kumagai K; Kubo T; Ohhori T
    Nihon Gan Chiryo Gakkai Shi; 1989 May; 24(5):948-56. PubMed ID: 2789265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adoptive immunotherapy in tumor-bearing mice with OK-432-induced killer cells.
    Ujiie T
    Jpn J Exp Med; 1988 Apr; 58(2):109-14. PubMed ID: 3261814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Augmentation by OK-432 of generation of culture-induced killer cells.
    Ujiie T
    Jpn J Exp Med; 1987 Jun; 57(3):153-61. PubMed ID: 3682231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced antitumor and immune-adjuvant activities of the sub-cellular fractions from Group A Streptococcus.
    Ryoyama K; Natsuume-Sakai S; Hirota H; Koshimura S
    Jpn J Exp Med; 1981 Dec; 51(6):335-44. PubMed ID: 7040746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor effect of OK-432-derived DNA: one of the active constituents of OK-432, a streptococcal immunotherapeutic agent.
    Oshikawa T; Okamoto M; Tano T; Sasai A; Kan S; Moriya Y; Ryoma Y; Saito M; Akira S; Sato M
    J Immunother; 2006; 29(2):143-50. PubMed ID: 16531815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytotoxic cells induced in tumor-bearing rats by a streptococcus preparation (OK-432).
    Hojo H; Hashimoto Y
    Gan; 1981 Oct; 72(5):692-9. PubMed ID: 7327369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation.
    Okamoto M; Furuichi S; Nishioka Y; Oshikawa T; Tano T; Ahmed SU; Takeda K; Akira S; Ryoma Y; Moriya Y; Saito M; Sone S; Sato M
    Cancer Res; 2004 Aug; 64(15):5461-70. PubMed ID: 15289356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New approach to management of malignant ascites with streptococcal preparation OK-432. III. OK-432 attracts natural killer cells through a chemotactic factor released from activated neutrophils.
    Hayashi Y; Torisu M
    Surgery; 1990 Jan; 107(1):74-84. PubMed ID: 2404351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies on the properties of a streptococcal preparation OK-432 (NSC-B116209) as an immunopotentiator. I. Activation of serum complement components and peritoneal exudate cells by group A streptococcus.
    Sakai S; Ryoyama K; Koshimura S; Migita S
    Jpn J Exp Med; 1976 Apr; 46(2):123-33. PubMed ID: 778447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of combined immunotherapy using two different BRMs; OK-432 and IL-2-cultured lymphocytes].
    Kan N; Hori T; Ohgaki K; Inamoto T; Kodama H; Tobe T
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1298-306. PubMed ID: 3488027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.